This is a working overview of SR9009, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-10. Anything still debated is marked as such rather than presented as settled.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
== SR == sr – (s) Serbian language (ISO 639-1 code) Sr – (s) Strontium SR (i) Sound Reinforcement Supply Route (s) Suriname (ISO 3166 digram) (i) Sveriges Radio (Swedish Radio Ltd) SR – (i) Sustained release of a drug SRAM (p) Scott (King), Ray (Day), SAM (Patterson) — founders of bicycle component manufacturer SRAM Corporation (p) Static Random Access Memory ("ess-ram") SR-ATGW – (i) Short-Range Anti-Tank Guided Weapon SRB – (i) Solid Rocket Booster SRBM – (i) Short-Range Ballistic Missile (cf. IRBM, ICBM) SRC – (i) Scheduled Removal Component srd – (s) Sardinian language (ISO 639-2 code) SRD (i) Science Requirements Document (s) Surinam dollar (ISO 4217 currency code) SRE - (i) Site Reliability Engineer(ing) SREL – (i) Savannah River Ecology Laboratory SRG (i) SACEUR Rover Group Special Republican Guard SRGW – (i) Short-Range Guided Weapon SRL (i) Savannah River Laboratory Single Rocket Launcher Survival Research Labs SRM – (i) Specified Risk Material(s) srp – (s) Serbian language (ISO 639-2 code) SRS – (i) Savannah River Site SRTP – (i) [Secure Real-time Transport Protocol]
Leukoreduced blood products are less likely to cause HLA alloimmunization (development of antibodies against specific blood types), febrile non-hemolytic transfusion reaction, cytomegalovirus infection, and platelet-transfusion refractoriness. Leukoreduction is performed using specialized filtration systems during blood processing, and in many countries it is routinely applied to most blood products before storage to reduce the risk of transfusion reactions and transmission of certain infections. Pathogen reduction treatment that involves, for example, the addition of riboflavin with subsequent exposure to UV light has been shown to be effective in inactivating pathogens (viruses, bacteria, parasites and white blood cells) in blood products. By inactivating white blood cells in donated blood products, riboflavin and UV light treatment can also replace gamma-irradiation as a method to prevent graft-versus-host disease (TA-GvHD).
blunt end A term used to describe the end of a double-stranded DNA molecule where the terminal nucleobases on each strand are base-paired with each other, such that neither strand has a single-stranded "overhang" of unpaired bases. This is in contrast to a so-called "sticky end", where an overhang is created by one strand being one or more bases longer than the other. Blunt ends and sticky ends are relevant when ligating multiple DNA molecules, e.g. in restriction cloning, because sticky-ended molecules will not readily anneal to each other unless they have matching overhangs; blunt-ended molecules do not anneal in this way, so special procedures must be used to ensure that fragments with blunt ends are joined in the correct places.
Sources: en.wikipedia.org
=== Autumn 2007: Deaths across north Texas === The spread of the drug to the outlying suburbs of Dallas was confirmed in September by the return of toxicology reports from the July 13 death of an 18-year-old student from McKinney, located northeast of Dallas in Collin County, and from two July deaths in nearby Tarrant County, one involving a 17-year-old male and the other, a 26-year-old male. Additional suburban deaths in September — in Irving to the west and Rockwall to the east — were believed to be linked to cheese heroin, though police cautioned toxicology reports would not likely be complete until November. The Tarrant County medical examiner's office announced on September 24 that a review of deaths in Tarrant County (west) and Denton County (north) showed an additional 15 deaths between 2004 and 2007 that appeared to be linked to "cheese," and Collin and Rockwall counties had reported one death each. These new figures brought the total number of deaths associated with cheese heroin in northern Texas to 40, a figure that included many older adults along with those age 18 and under.
2,5-DMA has been encountered as a novel designer drug, with capsules of 200 mg of the hydrobromide salt, equivalent to 170 mg of the hydrochloride salt. It was initially misrepresented as mescaline or MDA before being named DMA. According to Shulgin, this might be an effective dose level that has not been formally clinically explored.
==== Botulism ==== Infants can develop botulism after consuming honey contaminated with Clostridium botulinum endospores. While the risk honey poses to infant health is small, taking the risk is not recommended until after one year of age, and then giving honey is considered safe. Infantile botulism shows geographical variation. In the UK, only six cases were reported between 1976 and 2006, yet the US has much higher rates: 1.9 per 100,000 live births, 47.2% of which are in California.
Sources: en.wikipedia.org
== Protein content == The protein content of whole hemp seeds can vary between 20 and 25% depending on variety and environmental factors. Processing methods such as dehulling or oil fraction removal can increase the protein concentration in products like dehulled seed or hemp seed meal to over 50%. Hemp seeds are comparable with soybeans in terms of nutrition. They are high in protein, low in carbohydrates, and rich in dietary fiber and unsaturated fatty acids. After the oil is extracted from the hemp seeds, the residual mass is a protein-rich material useful for food processing. The protein in hemp seeds is made up of the two highly digestible globular types of proteins, edestin (60–80%) and 2S albumin, with edestin also being rich in the essential amino acids.
==== Ternary and more complex compounds ==== Although rarely encountered in anhydrous form, KOH is one of the dominant compounds of potassium from the commercial perspective. It is a strong base and highly corrosive. Illustrative of its hydrophilic character, as much as 1.21 kg of KOH can dissolve in a liter of water. KOH reacts readily with carbon dioxide (CO2) to produce potassium carbonate (K2CO3), and in principle could be used to remove traces of the gas from air. Like the closely related sodium hydroxide, KOH reacts with fats to produce soaps. Potassium-based soaps are used in soap dispensers because they more soluble in water than sodium soaps. Nitrate, nitrite, sulfate, and various phosphates also form potassium salts, all white solids, that are widely used. Illustrating the thermal stability typical for these materials, potassium nitrate, sodium nitrate, and sodium nitrite form a eutectic, which remains liquid from 142 to 600 °C. Sodium and potassium salts display virtually identical properties in aqueous solution, but their differing solubilities are of practical value. The distinctive solubility of potassium heptafluorotantalate (K2[TaF7]) allows the purification of tantalum from the otherwise persistent contaminant of niobium. The solubility of the K+ compound differs strikingly from that for the Na+ compound in the pairs sodium tetraphenylborate/potassium tetraphenylborate, sodium cobaltinitrite/potassium cobaltinitrite, and sodium hexachloroplatinate/ potassium hexachloroplatinate. These differences are the bases for gravimetric analysis for K+.
The bactericidal effects of β-lactam antibiotics are achieved through inhibition of the bacterial cell wall synthesis. The cell wall of both gram-positive and gram-negative bacteria is a tight covalently bound and cross-linked peptidoglycan network and essential for bacterial growth, cell division and cellular structure. Therefore, bacteria need enzymes that can cleave the cell wall during bacterial growth and cell division. The cell wall of bacteria is built up in two steps from the outside of the cell. In the first step, molecules of disaccharide units linked with peptides on their ends are transported from the cytoplasm of the bacteria and joined on the outside of the wall by a transglycolase. In the second step, a transpeptidase links together long polysaccharide chains which are linked together through peptide bonds. The amino acid sequence of D-alanyl-D-alanine is recognized by the transpeptidase at the end of the peptide chain. The enzyme cleaves off the alanine on the terminal end and joins the remainder to a peptide chain from an adjacent polysaccharide. This transpeptidation reaction is inhibited by β-lactam antibiotics like cephalosporins. Because of this inhibition the antibiotics are most effective when the bacteria are in the logarithmic phase of growth, where then they are synthesizing the cell wall. If the bacteria are in the stationary phase of growth, then there is no wall synthesizing in progress, and the antibiotics have much lower effect.
Lipoatrophy is the term describing the localized loss of fat tissue. This may occur as a result of subcutaneous injections of insulin in the treatment of diabetes, from the use of human growth hormone or from subcutaneous injections of copaxone used for the treatment of multiple sclerosis. In the latter case, an injection may produce a small dent at the injection site. Lipoatrophy occurs in HIV-associated lipodystrophy, one cause of which is an adverse drug reaction that is associated with some antiretroviral medications. A more general term for an abnormal or degenerative condition of the entire body's adipose tissue is lipodystrophy.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.